Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer

- Transaction Will Maximize the Access and Uptake of COSELA^® (trilaciclib), the First and Only Proactive Multilineage Myeloprotection Agent -

- G1 Stockholders to Receive U.S. $7.15 Per Share in Cash -